Press Release

KUALA LUMPUR, MALAYSIA – May 18, 2026 – IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that IQVIA Malaysia has been awarded the CRO of the Year Award by Clinical Research Malaysia, presented by YB Datuk Seri Haji Dr. Dzulkefly bin Ahmad, Minister of Health.

IQVIA has received the CRO of the Year recognition from Clinical Research Malaysia for nine consecutive years, demonstrating the team’s sustained commitment to high quality clinical research delivery, strong site collaboration and patient-centric innovation.

IQVIA Malaysia also received the Publication of the Year Award for its white paper, Malaysia: The New Destination for Early Phase Trials, which outlines the country’s growing role in early-phase clinical trials, supported by its strong clinical infrastructure, diverse patient population, and a supportive regulatory environment.

Benjamin Laverty, Vice President of Clinical Operations for Southeast Asia, India, Australia and New Zealand, said, “We are truly honored to receive this award, recognizing our longstanding contribution to clinical research in Malaysia. We sincerely thank CRM for their dedication and support of Malaysia's clinical research ecosystem. This award is testament to our joint efforts to drive industry-sponsored clinical research, enabling innovative therapies for patients in Malaysia.”

Malaysia is increasingly recognized as a promising hub for early-phase clinical research, including First-In-Human (FIH) studies. With an established history of hosting international trials, the country has steadily built a reputation for quality, reliability and operational readiness. IQVIA Malaysia offers comprehensive services, clinical and commercial solutions across biopharmaceutical, medical device and broader life sciences sector.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high quality health data, Healthcare grade AI^®, advanced analytics, the latest technologies, and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology, and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers, and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Media Contacts

Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com) +1.973.541.3558

Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com) +1.919.923.6785